Leo Pharma Archives

News and Trends 21 Nov 2018

Leo Pharma Enters Partnership to Develop Topical Treatment for Rare Skin Cancer

The Danish company Leo Pharma and the US biotech PellePharm have joined forces to develop a topical treatment for rare forms of skin cancer. In the partnership, dermatology specialist Leo Pharma is paying PellePharm €61M. This is to fund a Phase III trial of PellePharm’s topical drug to treat the skin cancer Gorlin syndrome, which has no […]

November 21, 2018 - 2 minutesmins - By Jonathan Smith

In Depth 17 Oct 2017

Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis

Though the psoriasis market is teeming with effective products, companies have developed ways to devise new, more effective modes of treatment. Psoriasis is a common autoimmune disorder that affects the skin, often causing patches of dry, itchy, and painful lesions. In severe cases, people can develop psoriatic arthritis, which can lead to painful inflammation in […]

October 17, 2017 - 7 minutesmins - By Diana Kwon

News and Trends 20 Jul 2017

Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links

Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that targets IL-17a. Published 22/05/2017 The EMA has taken up a positive opinion for Leo Pharma’s psoriasis drug brodalumab, even though the drug has been associated with suicidal behavior. Brodalumab, a fully human antibody targeting the […]

July 20, 2017 - 3 minutesmins - By Melanie De Almeida

More News! 20 Jun 2017

Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma

argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly. Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to […]

June 20, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 2 Nov 2016

Antibody Therapies are here to Revolutionize Dermatology

Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership! MorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos […]

November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2016

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

leo pharma astrazeneca dermatology biologics

News and Trends 4 Jul 2016

Danish Pharma enters in the Biologics arena with Antibody Buy-out

Leo Pharma is acquiring rights to two of AstraZeneca‘s candidates. The targeted indications are atopic dermatitis and psoriasis – autoimmune conditions getting more and more attention. Based near Copenhagen (Denmark), Leo Pharma specializes in dermatological therapies – particularly topical treatments. The company is not shy about its acquisitions, having entered a €675M deal to buy Japanese […]

July 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

llama leo pharma argen x skin milestone inflammatory

News and Trends 3 Feb 2016

When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease

ArGEN-X in Ghent (Belgium) combines the diversity of the llama immune system with a clinical antibody pipeline which Leo Pharma (Denmark), is developing to treat inflammatory skin conditions. These llama mAb platforms allow arGEN-X to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. This is a similar approach to which Ablynx […]

February 3, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Dec 2015

Infographic: The Anatomy of European Biotech

Which part of our body do European biotechs prefer to target? And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis…. Here is an infographic-based overview of some of the target areas that European […]

December 10, 2015 - 1 minutemin - By Nicolas Sainte-Foie

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us